EGFR and amyotrophic lateral sclerosis: Erlotinib, an EGFR inhibitor marketed for the treatment of non-small cell lung carcinoma, presented an opportunity to determine if inhibition of this pathway would also have a beneficial effect in the SOD1G93A mouse model of ALS.